Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.